Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway

Xuedan Han; Jialei Liu; Yidong Zhang; Eric Tse; Qiyi Yu; Yu Lu; Yi Ma; Lufeng Zheng

doi:10.1016/j.jpha.2024.100984

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2024 > Accepted Manu

Xuedan Han, Jialei Liu, Yidong Zhang, Eric Tse, Qiyi Yu, Yu Lu, Yi Ma, Lufeng Zheng. Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.100984

Citation:

Xuedan Han, Jialei Liu, Yidong Zhang, Eric Tse, Qiyi Yu, Yu Lu, Yi Ma, Lufeng Zheng. Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.100984

Citation:

Xuedan Han, Jialei Liu, Yidong Zhang, Eric Tse, Qiyi Yu, Yu Lu, Yi Ma, Lufeng Zheng. Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.100984

PDF( 24992 KB)

Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway

doi: 10.1016/j.jpha.2024.100984

Xuedan Han¹,
Jialei Liu¹,
Yidong Zhang¹,
Eric Tse^1,2,
Qiyi Yu¹,
Yu Lu¹,
Yi Ma^{1
,
,},
Lufeng Zheng^{1
,
,}

1 Lab of Natural Medicines, Department of Biomedical Engineering, School of Engineering, School of Pharmacy, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China;
2 Sino Biopharmaceutical Group Limited, Beijing, 100026, China

Received Date: Nov. 11, 2023
Rev Recd Date: Apr. 19, 2024
Available Online: Apr. 26, 2024

Abstract

Abstract

Anlotinib has strong antiangiogenic effects and leads to vessel normalization. However, the "window period" characteristic in regulating vessel normalization by anlotinib cannot fully explain the long-term survival benefits achieved through combining it with other drugs. In this study, through RNA sequencing and label-free quantitative proteomics analysis, we discovered that anlotinib regulated the expression of components of the extracellular matrix (ECM), leading to a significant reduction in ECM stiffness. Our bioinformatic analysis revealed a potential positive relationship between the ECM pathway and gefitinib resistance, poor treatment outcomes for programmed death 1 (PD-1) targeting, and unfavourable prognosis following chemotherapy in lung cancer patients. We administered anlotinib in combination with these antitumour drugs and visualized their distribution using fluorescent labelling in various tumour types. Notably, our results demonstrated that anlotinib prolonged the retention time and distribution of antitumour drugs at the tumour site. Moreover, the combination therapy induced notable loosening of the tumour tissue structure. This reduction was associated with decreased interstitial fluid pressure and tumour solid pressure. Additionally, we observed that anlotinib effectively suppressed the RhoA/ROCK signalling pathway. These findings suggest that, in addition to its antiangiogenic and vessel normalization effects, anlotinib can increase the distribution and retention of antitumour drugs in tumours by modulating ECM expression and physical properties through the RhoA/ROCK signalling pathway. These valuable insights contribute to the development of combination therapies aimed at improving tumour targeting in cancer treatment.
- Anlotinib,
- Extracellular matrix,
- Interstitial fluid pressures,
- Tumour solid pressure,
- RhoA/ROCK

FullText(HTML)

References(45)

References

[1]	B.M. Bordeau, J.P. Balthasar, Strategies to enhance monoclonal antibody uptake and distribution in solid tumors, Cancer Biol. Med. 18(2021) 649-664.
[2]	A.I. Minchinton, I.F. Tannock, Drug penetration in solid tumours, Nat. Rev. Cancer 6(2006) 583-592.
[3]	T. Stylianopoulos, R.K. Jain, Combining two strategies to improve perfusion and drug delivery in solid tumors, Proc. Natl. Acad. Sci. USA 110(2013) 18632-18637.
[4]	G. Shen, F. Zheng, D. Ren, et al., Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development, J. Hematol. Oncol. 11(2018), 120.
[5]	Q. Xu, J. Wang, Y. Sun, et al., Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: A multicenter, single-arm, prospective phase II trial, J. Clin. Oncol. 40(2022) 1795-1805.
[6]	C. Lan, J. Zhao, F. Yang, et al., Anlotinib combined with TQB2450 in patients with platinum-resistant or-refractory ovarian cancer: A multi-center, single-arm, phase 1b trial, Cell Rep. Med. 3(2022), 100689.
[7]	P. Wang, X. Fang, T. Yin, et al., Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study, Front. Oncol. 11(2021), 628124.
[8]	Y. Su, B. Luo, Y. Lu, et al., Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma, Clin. Cancer Res. 28(2022) 793- 809.
[9]	P. Carmeliet, R.K. Jain, Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases, Nat. Rev. Drug Discov. 10(2011) 417-427.
[10]	J.D. Martin, G. Seano, R.K. Jain, Normalizing function of tumor vessels: Progress, opportunities, and challenges, Annu. Rev. Physiol. 81(2019) 505-534.
[11]	T. Chu, R. Zhong, H. Zhong, et al., Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC, J. Thorac. Oncol. 16(2021) 643-652.
[12]	J. Zhou, Y. Sun, W. Zhang, et al., Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis, Hepatology 77(2023) 65-76.
[13]	V.M. Perez, J.F. Kearney, J.J. Yeh, The PDAC extracellular matrix: A review of the ECM protein composition, tumor cell interaction, and therapeutic strategies, Front. Oncol. 11(2021), 751311.
[14]	Y. Jiang, H. Zhang, J. Wang, et al., Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy, J. Hematol. Oncol. 15(2022), 34.
[15]	H. Jiang, H. Wei, H. Wang, et al., Zeb1-induced metabolic reprogramming of glycolysis is essential for macrophage polarization in breast cancer, Cell Death Dis. 13(2022), 206.
[16]	K.R. Levental, H. Yu, L. Kass, et al., Matrix crosslinking forces tumor progression by enhancing integrin signaling, Cell 139(2009) 891-906.
[17]	C. Upagupta, C. Shimbori, R. Alsilmi, et al., Matrix abnormalities in pulmonary fibrosis, Eur. Respir. Rev. 27(2018), 180033.
[18]	F. Wei, Y. Su, Y. Quan, et al., Anticoagulants enhance molecular and cellular immunotherapy of cancer by improving tumor microcirculation structure and function and redistributing tumor infiltrates, Clin. Cancer Res. 29(2023) 2525- 2539.
[19]	S. Singh, L.A. Ray, P. Shahi Thakuri, et al., Organotypic breast tumor model elucidates dynamic remodeling of tumor microenvironment, Biomaterials 238(2020), 119853.
[20]	E.K. Choi, J.G. Kim, H.J. Kim, et al., Regulation of RhoA GTPase and novel target proteins for ROCK, Small GTPases 11(2020) 95-102.
[21]	K. Bera, A. Kiepas, I. Godet, et al., Extracellular fluid viscosity enhances cell migration and cancer dissemination, Nature 611(2022) 365-373.
[22]	S.J. Adua, A. Arnal-Estapé, M. Zhao, et al., Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer, Nat. Commun. 13(2022), 7690.
[23]	W. Chen, Y. Yuan, C. Li, et al., Modulating tumor extracellular matrix by simultaneous inhibition of two cancer cell receptors, Adv. Mater. Deerfield Beach Fla 34(2022), e2109376.
[24]	J. Xu, X. Yang, X. Tang, et al., pH-Responsive nanomicelles for breast cancer nearinfrared fluorescence imaging and chemo/photothermal therapy, J. Mater. Chem. C 10(2022) 16283-16293.
[25]	H. Wang, J. Chen, C. Xu, et al., Cancer nanomedicines stabilized by π-π stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations, Theranostics 7(2017) 3638-3652.
[26]	P. Zhong, J. Zhang, C. Deng, et al., Glutathione-sensitive hyaluronic acid-SSmertansine prodrug with a high drug content: Facile synthesis and targeted breast tumor therapy, Biomacromolecules 17(2016) 3602-3608.
[27]	J. Zheng, Y. Shen, Z. Xu, et al., Near-infrared off-on fluorescence probe activated by NTR for in vivo hypoxia imaging, Biosens. Bioelectron. 119(2018) 141-148.
[28]	A. A., E. Levantini, J.T. Teo, et al., Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer, EMBO Mol. Med. 10(2018), e8313.
[29]	S. Hwang, A.Y. Kwon, J.Y. Jeong, et al., Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer, Sci. Rep. 10(2020), 643.
[30]	A. Subramanian, P. Tamayo, V.K. Mootha, et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. USA 102(2005) 15545-15550.
[31]	M.I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2, Genome Biol. 15(2014), 550.
[32]	A. Fiorio Pla, H.L. Ong, K.T. Cheng, et al., TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling, Oncogene 31(2012) 200-212.
[33]	G. Van Goietsenoven, V. Mathieu, F. Lefranc, et al., Narciclasine as well as other Amaryllidaceae isocarbostyrils are promising GTP-ase targeting agents against brain cancers, Med. Res. Rev. 33(2013) 439-455.
[34]	H. Lei, D. Wu, J. Wang, et al., C1q/tumor necrosis factor-related protein-6 attenuates post-infarct cardiac fibrosis by targeting RhoA/MRTF-a pathway and inhibiting myofibroblast differentiation, Basic Res. Cardiol. 110(2015), 35.
[35]	S. Suzuki, M. Furuhashi, Y. Tsugeno, et al., Comparison of the drug-induced efficacies between omidenepag isopropyl, an EP2 agonist and PGF2α toward TGF- β2-modulated human trabecular meshwork (HTM) cells, J. Clin. Med. 11(2022), 1652.
[36]	Y. Ida, A. Umetsu, M. Furuhashi, et al., The EP2 agonist, omidenepag, alters the physical stiffness of 3D spheroids prepared from human corneal stroma fibroblasts differently depending on the osmotic pressure, FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 36(2022), e22067.
[37]	J.C. Marine, M.S. Soengas, Cell position matters in tumour development, Nature 604(2022) 248-250.
[38]	G. Runel, N. Lopez-Ramirez, J. Chlasta, et al., Biomechanical properties of cancer cells, Cells 10(2021), 887.
[39]	P. Fan, H. Qiang, Z. Liu, et al., Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy, Front. Immunol. 13(2022), 937924.
[40]	T. Zhang, Y. Jia, Y. Yu, et al., Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy, Adv. Drug Deliv. Rev. 186(2022), 114319.
[41]	J.S. Kim, J.E. Park, S.H. Choi, et al., ECM-targeting bacteria enhance chemotherapeutic drug efficacy by lowering IFP in tumor mouse models, J. Control. Release 355(2023) 199-210.
[42]	Z. Huang, X. Mao, R. Wu, et al., RhoA/ROCK pathway mediates the effect of oestrogen on regulating epithelial-mesenchymal transition and proliferation in endometriosis, J. Cell. Mol. Med. 24(2020) 10693-10704.
[43]	X. Wei, H. Lou, D. Zhou, et al., TAGLN mediated stiffness-regulated ovarian cancer progression via RhoA/ROCK pathway, J. Exp. Clin. Cancer Res. 40(2021), 292.
[44]	Y. Chi, Y. Chen, W. Jiang, et al., Deficiency of integrin β4 results in increased lung tissue stiffness and responds to substrate stiffness via modulating RhoA activity, Front. Cell Dev. Biol. 10(2022), 845440.
[45]	C. Han, S. Ye, C. Hu, et al., Clinical activity and safety of penpulimab (anti-PD-1) with anlotinib as first-line therapy for unresectable hepatocellular carcinoma: An open-label, multicenter, phase ib/II trial (AK105-203), Front. Oncol. 11(2021), 684867